Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
134,746,897
-
Total 13F shares
-
107,228,944
-
Share change
-
+796,981
-
Total reported value
-
$146,966,286
-
Put/Call ratio
-
0%
-
Price per share
-
$1.37
-
Number of holders
-
119
-
Value change
-
-$1,500,597
-
Number of buys
-
55
-
Number of sells
-
70
Institutional Holders of Tango Therapeutics, Inc. - Common stock, par value $0.001 per share (the "Shares") (TNGX) as of Q1 2025
As of 31 Mar 2025,
Tango Therapeutics, Inc. - Common stock, par value $0.001 per share (the "Shares") (TNGX) was held by
119 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
107,228,944 shares.
The largest 10 holders included
TRV GP IV, LLC, TCG Crossover Management, LLC, EcoR1 Capital, LLC, Boxer Capital Management, LLC, Nextech Invest, Ltd., GILEAD SCIENCES, INC., FARALLON CAPITAL MANAGEMENT LLC, BlackRock, Inc., VANGUARD GROUP INC, and T. Rowe Price Investment Management, Inc..
This page lists
119
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.